Detalhe da pesquisa
1.
Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial.
Ann Rheum Dis
; 82(1): 154-160, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35961761
2.
Secukinumab provides sustained improvement in nail psoriasis, signs and symptoms of psoriatic arthritis and low rate of radiographic progression in patients with concomitant nail involvement: 2-year results from the Phase III FUTURE 5 study.
Clin Exp Rheumatol
; 40(5): 952-959, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-34494957
3.
Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data.
Acta Derm Venereol
; 102: adv00698, 2022 Apr 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-35146532
4.
Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial.
Lancet
; 395(10235): 1496-1505, 2020 05 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32386593
5.
Sequential knockoffs for continuous and categorical predictors: With application to a large psoriatic arthritis clinical trial pool.
Stat Med
; 40(14): 3313-3328, 2021 06 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-33899260
6.
Secukinumab's effect on structural damage progression in psoriatic arthritis: longitudinal mixture modelling of FUTURE-1 and FUTURE-5.
Clin Exp Rheumatol
; 39(5): 931-937, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33253089
7.
Secukinumab Efficacy in Psoriatic Arthritis: Machine Learning and Meta-analysis of Four Phase 3 Trials.
J Clin Rheumatol
; 27(6): 239-247, 2021 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32015257
8.
Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5.
Rheumatology (Oxford)
; 59(6): 1325-1334, 2020 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31586420
9.
Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials.
Ann Rheum Dis
; 78(4): 473-479, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30674475
10.
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis.
N Engl J Med
; 373(14): 1329-39, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26422723
11.
Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study.
Ann Rheum Dis
; 77(6): 890-897, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29550766
12.
Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1).
Ann Rheum Dis
; 76(1): 203-207, 2017 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-27169431
13.
Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study.
Rheumatology (Oxford)
; 56(11): 1993-2003, 2017 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28968735
14.
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
; 386(9999): 1137-46, 2015 Sep 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-26135703
15.
Efficacy and Safety of Secukinumab in US Patients with Psoriatic Arthritis: A Subgroup Analysis of the Phase 3 FUTURE Studies.
Rheumatol Ther
; 11(3): 675-689, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38625671
16.
Correlation of 18F-FDG PET/CT assessments with disease activity and markers of inflammation in patients with early rheumatoid arthritis following the initiation of combination therapy with triple oral antirheumatic drugs.
Eur J Nucl Med Mol Imaging
; 40(3): 403-10, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23229747
17.
Quantification of pre-existing radiographic damage and its relationship with joint activity and long-term clinical outcomes with secukinumab therapy in patients with psoriatic arthritis.
Arthritis Res Ther
; 24(1): 283, 2022 12 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-36578042
18.
Accelerated pathological and clinical nephritis in systemic lupus erythematosus-prone New Zealand Mixed 2328 mice doubly deficient in TNF receptor 1 and TNF receptor 2 via a Th17-associated pathway.
J Immunol
; 182(4): 2532-41, 2009 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-19201910
19.
Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis.
RMD Open
; 7(3)2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34795065
20.
Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTURE 5 study.
RMD Open
; 7(2)2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34330846